ProCE Banner Activity

CME

A Review of Current and Emerging Treatment Options for Myelodysplastic Syndromes

Multimedia
Learn about current and emerging treatment options for myelodysplastic syndromes from expert faculty in this webcast from a live CCO symposium.

Physicians: Maximum of 2.00 AMA PRA Category 1 Credits

Released: January 13, 2022

Expiration: January 12, 2023

No longer available for credit.

Share

Faculty

Michael R. Savona

Michael R. Savona, MD, FACP

Director of Leukemia Research
Senior Investigator, Hematologic Malignancies Research and Drug Development
Sarah Cannon Research Institute
Sarah Cannon Center for Blood Cancers
Tennessee Oncology
Nashville, Tennessee

Jacqueline S. Garcia

Jacqueline S. Garcia, MD

Assistant Professor of Medicine
Harvard Medical School
Dana-Farber Cancer Institute
Boston, Massachusetts 

Amer Zeidan

Amer Zeidan, MBBS, MPH

Associate Professor of Medicine (Hematology)
Chief, Division of Hematologic Malignancies
Yale Comprehensive Cancer Center and Smilow Cancer Hospital
New Haven, Connecticut

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

AbbVie Inc.

Gamida Cell Ltd

Geron

Gilead Sciences, Inc.

Karyopharm Therapeutics Inc.

Takeda Pharma USA Inc Takeda Onc Co

Target Audience

This program is intended for physicians and other healthcare professionals who care for patients with MDS.

Learning Objectives

Upon completion of this activity, participants should be able to:
  • Integrate novel management options for managing MDS-related anemia
  • Evaluate emerging treatment options for the treatment of patients with lower-, intermediate-, and high-risk MDS
  • Consider available treatment options and clinical trial enrollment for the management MDS
  • Plan novel therapeutic options for patients with relapsed/refractory disease
  • Identify patients with MDS who are candidates for ongoing clinical trials

Disclosure

Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:

Program Director Disclosure

Program Director

Michael R. Savona, MD, FACP

Director of Leukemia Research
Senior Investigator, Hematologic Malignancies Research and Drug Development
Sarah Cannon Research Institute
Sarah Cannon Center for Blood Cancers
Tennessee Oncology
Nashville, Tennessee

Michael J. Savona, MD, has disclosed that he has received consulting fees from AbbVie, Bristol-Myers Squibb, CTI, Geron, Karyopharm, Novartis, Ryvu, Sierra Oncology, Taiho, Takeda, and TG Therapeutics; has received funds for research support from Astex, ALX Oncology, Incyte, Takeda, and TG Therapeutics; and has ownership interest in Karyopharm and Ryvu.

Faculty Disclosure

Primary Author

Jacqueline S. Garcia, MD

Assistant Professor of Medicine
Harvard Medical School
Dana-Farber Cancer Institute
Boston, Massachusetts 

Jacqueline S. Garcia, MD, has disclosed that she has received consulting fees from AbbVie, Astellas, and Takeda and funds for research support from AbbVie, AstraZeneca, Genentech, Pfizer, and Prelude.

Amer Zeidan, MBBS, MPH

Associate Professor of Medicine (Hematology)
Chief, Division of Hematologic Malignancies
Yale Comprehensive Cancer Center and Smilow Cancer Hospital
New Haven, Connecticut

Amer Zeidan, MBBS, MHS, has disclosed that he has received funds for research support from AbbVie, ADC Therapeutics, Amgen, Aprea, Astex, Boehringer Ingelheim, Cardiff Oncology, Celgene/Bristol-Myers Squibb, Incyte, Medimmune/AstraZeneca, Novartis, Otsuka, Pfizer, Takeda, and Trovagene and consulting fees from Acceleron, Agios, Amgen, Aprea, Astellas, Astex, BeyondSpring, Boehringer Ingelheim, Cardiff Oncology, Cardinal Health, Celgene/Bristol-Myers Squibb, Daiichi Sankyo, Epizyme, Gilead Sciences, Incyte, Ionis, Janssen, Jazz, Kura, Novartis, Otsuka, Pfizer, Seattle Genetics, Syndax, Taiho, Takeda, Trovagene, and Tyme.

Staff Disclosure

Staff

Marie N. Becker, PhD

Scientific Director

Marie N. Becker, PhD, has no relevant conflicts of interest to report.

Gordon Kelley,

Clinical Editor
Clinical Care Options, LLC

Gordon Kelley has no relevant conflicts of interest to report.

Krista Marcello,

Associate Managing Editor

Krista Marcello, PhD, has no relevant conflicts of interest to report.

Jim Mortimer,

Product Director, Hematology/Oncology
Clinical Care Options, LLC

Jim Mortimer has no relevant conflicts of interest to report.

Kevin Obholz, PhD

Editorial Director, Hematology/Oncology

Kevin Obholz, PhD, has no relevant conflicts of interest to report.

Shara Pantry, PhD

Associate Scientific Director

Shara Pantry, PhD, has no relevant conflicts of interest to report.

Timothy A. Quill, PhD

Senior Managing Editor

Timothy A. Quill, PhD, has no relevant conflicts of interest to report.

June Wasserstrom,

Director, CME Program Development

June Wasserstrom has no relevant conflicts of interest to report.

Instructions for Credit

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Credit Designation

CCO designates this enduring material for a maximum of 2.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Additional Information

Participation in this self-study activity should be completed in approximately 2 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from January 13, 2022, through January 12, 2023:

1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 65% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.

Program Medium

This program has been made available online.


Goal


The goal of this activity is to improve and accelerate the awareness, understanding, and integration of current and emerging best practices in the treatment of myelodysplastic syndromes.